Is there an ideal cutoff for α‐fetoprotein as an exclusion criterion for liver transplantation?
Angelo Alves Mattos, Luciana Santos Schraiber, Maria Lucia Zanotell, Guido Cantisani – 11 July 2014
Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012
Richard S. Hoehn, Gregory C. Wilson, Koffi Wima, Samuel F. Hohmann, Emily F. Midura, E. Steve Woodle, Daniel E. Abbott, Ashish Singhal, Shimul A. Shah – 11 July 2014 – A complete evaluation of living donor liver transplantation (LDLT) in the United States has been difficult because of the persistent low volume and the lack of adequate comparisons with deceased donor liver transplantation (DDLT). Recent reports have suggested outcomes equivalent to those for DDLT, but these studies did not adjust for differences in recipient selection.
Reply
Kaoru Tsuchiya, Yasuhiro Asahina, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi – 11 July 2014
Cooperation of C/EBP family proteins and chromatin remodeling proteins is essential for termination of liver regeneration
Jingling Jin, Il‐Hwa Hong, Kyle Lewis, Polina Iakova, Meghan Breaux, Yanjun Jiang, Emily Sullivan, Nicole Jawanmardi, Lubov Timchenko, Nikolai A. Timchenko – 9 July 2014 – Liver cancer is the fifth most common cancer. A highly invasive surgical resection of the liver tumor is the main approach used to eliminate the tumor. Mechanisms that terminate liver regeneration when the liver reaches the original size are not known.
Cooperation of C/EBP family proteins and chromatin remodeling proteins is essential for termination of liver regeneration
Jingling Jin, Il‐Hwa Hong, Kyle Lewis, Polina Iakova, Meghan Breaux, Yanjun Jiang, Emily Sullivan, Nicole Jawanmardi, Lubov Timchenko, Nikolai A. Timchenko – 9 July 2014 – Liver cancer is the fifth most common cancer. A highly invasive surgical resection of the liver tumor is the main approach used to eliminate the tumor. Mechanisms that terminate liver regeneration when the liver reaches the original size are not known.
Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a
Thomas H.R. Carlsen, Jannie Pedersen, Jannick C. Prentoe, Erick Giang, Zhen‐Yong Keck, Lotte S. Mikkelsen, Mansun Law, Steven K.H. Foung, Jens Bukh – 8 July 2014 – Human monoclonal antibodies (HMAbs) with neutralizing capabilities constitute potential immune‐based treatments or prophylaxis against hepatitis C virus (HCV). However, lack of cell culture‐derived HCV (HCVcc) harboring authentic envelope proteins (E1/E2) has hindered neutralization investigations across genotypes, subtypes, and isolates.
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
Hendrik Vilstrup, Piero Amodio, Jasmohan Bajaj, Juan Cordoba, Peter Ferenci, Kevin D. Mullen, Karin Weissenborn, Philip Wong – 8 July 2014
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
Hendrik Vilstrup, Piero Amodio, Jasmohan Bajaj, Juan Cordoba, Peter Ferenci, Kevin D. Mullen, Karin Weissenborn, Philip Wong – 8 July 2014